J Allergy Clin Immunol. 1981 Jul; 68(1): 33-40.

Local intranasal immunotherapy for ragweed allergic rhinitis. I. Clinical response.

Nickelsen JA, Goldstein S, Mueller U, Wypych J, Reisman RE, Arbesman CE.

Local nasal immunotherapy (LNIT) of ragweed allergic rhinitis was studied in a double-blind controlled trial. Sixty-seven subjects were divided into three groups. Twenty-one received unmodified ragweed extract (RW), 24 received a glutaraldehyde polymer of ragweed extract (PRW), and 22 received placebo. Mean symptom/medication scores during the season were 2.12, 2.76, and 3.93 for the RW, PRW, and placebo groups, respectively. Both RW- and the PRW-treated group scores were significantly lower than those of the placebo group (p less than 0.01, and p less than 0.025, respectively). The results of the patients' self-evaluations indicated that therapy was effective in 71%, 59%, and 41% for the RW-, PRW-, and placebo-treated groups, respectively. Adverse reactions to treatment were limited to the upper respiratory tract and were noted by all patients. They were significantly more severe in the RW-treated patients than those in the PRW- or placebo-treated groups. We conclude that LNIT is an effective therapy for ragweed allergic rhinitis. The use of a PRW decreased adverse reactions significantly while slightly decreasing the therapeutic benefit.